Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France

As of February 2022, more than 130 million Covid vaccine doses had been distributed in France. During the first year of relevant vaccination, 128,766 adverse events (AE) were reported and analysed, as compared to an average of 40,000 per year for all drugs combined in the pre-pandemic years. A weekl...

Descripción completa

Detalles Bibliográficos
Autores principales: Crommelynck, S., Thill, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492382/
https://www.ncbi.nlm.nih.gov/pubmed/36152793
http://dx.doi.org/10.1016/j.idnow.2022.09.018
Descripción
Sumario:As of February 2022, more than 130 million Covid vaccine doses had been distributed in France. During the first year of relevant vaccination, 128,766 adverse events (AE) were reported and analysed, as compared to an average of 40,000 per year for all drugs combined in the pre-pandemic years. A weekly monitoring committee was set up. Through enhanced pharmacovigilance, by February 2022, 49 safety signals had been identified nationwide and submitted to the EMA. For example, very few cases of myocarditis and pericarditis were reported. In children, 9 multisystem inflammatory syndromes were reported.

Ejemplares similares